Welcome to our dedicated page for RIGEL PHARMACEUTICALS SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Rigel Pharmaceuticals, Inc. common stock. They disclose beneficial ownership of 1,672,000 shares, representing 8.95% of the outstanding common stock as of June 30, 2026.
The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager, giving it shared voting and dispositive power over all 1,672,000 shares. Neither Armistice Capital nor Mr. Boyd has sole voting or dispositive power, and the Master Fund has the right to receive dividends and sale proceeds on these securities.
Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of Rigel Pharmaceuticals, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 1,843,504 shares of common stock, representing 9.9% of the class, based on 18,679,864 shares outstanding as of July 30, 2026.
The Soleus entities and Guy Levy report shared voting and dispositive power over all 1,843,504 shares and no sole voting or dispositive power. Each reporting person disclaims beneficial ownership of the shares beyond what is required for Section 13(d) reporting under the Exchange Act.
Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million, including record net product sales of $67.0 million, up 14% year over year, and $11.7 million of contract revenues from collaborations. Net income was $17.3 million, or $0.88 per diluted share.
Growth in product sales was led by TAVALISSE at $47.4 million (up 18%) and REZLIDHIA at $8.9 million (up 27%), while GAVRETO declined to $10.7 million. Collaboration revenue reflected $5.8 million from Kissei, $5.0 million from Grifols and $0.3 million from Medison; the prior-year quarter included $40.0 million of non-cash revenue from a Lilly cost-share release, which lowered year-over-year reported revenues and earnings. For the first half of 2026, total revenues were $137.5 million and net income was $25.9 million.
Rigel entered an exclusive global license with Arvinas and Pfizer for VEPPANU, paying a $70.0 million upfront payment and preparing for U.S. commercial availability in mid-August 2026. Cash, cash equivalents and short-term investments were $95.3 million at June 30, 2026. The company raised its 2026 total revenue outlook to $285–$295 million, including $255–$265 million in net product sales and about $30 million in contract revenues, excluding VEPPANU, and continues to anticipate positive full-year net income.
Rigel Pharmaceuticals, Inc. reported total revenues of 78,703 (in thousands) for the quarter ended June 30, 2026, generating net income of 17,290 (in thousands), or $0.88 diluted earnings per share. For the first six months of 2026, revenues were 137,521 (in thousands) and net income was 25,944 (in thousands). Product sales grew, while contract revenues declined versus 2025, which had included a 39,981 (in thousands) release of a Lilly cost share liability.
Cash, cash equivalents, restricted cash and short-term investments totaled 95,386 (in thousands) at June 30, 2026, with stockholders’ equity of 425,422 (in thousands). The company repaid a prior term loan and entered a new revolving credit facility, with $40.0 million outstanding at quarter end. TAVALISSE net product sales were $84.7 million for the six months ended June 30, 2026, up 24% from $68.5 million, REZLIDHIA sales were $17.0 million, and GAVRETO sales were $20.3 million. Rigel licensed VEPPANU from Arvinas and Pfizer, paying a $70.0 million upfront fee and gaining rights to a fourth FDA-approved product expected to launch in mid-August 2026, while its prior global collaboration with Lilly for ocadusertib was terminated, with rights reverting to Rigel.
HANNAH ALISON L. reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 shares of common stock in the form of Restricted Stock Units. These RSUs vest annually over four years from July 8, 2026, with the first vesting on July 8, 2027. Following adjustments, including the cancellation of 5,750 RSUs for no consideration, she holds 35,025 shares of common stock directly.
Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.
Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.
Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction. After the sale, she directly holds 10,125 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025 and, according to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than for investment purposes.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey received a fully vested employee stock option tied to a performance goal. The award covers 7,394 shares of common stock at an exercise price of $22.49 per share. The performance metric was confirmed as met on June 17, 2026, triggering vesting, and the option expires on January 29, 2035. This is a compensation-related grant, not an open-market share purchase or sale.
Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options. On June 17, 2026, performance metrics were determined to be met for options covering 9,375 shares at an exercise price of $14.90 and 7,394 shares at $22.49.
Both option grants became fully vested on June 17, 2026. The 9,375-share grant was originally made on March 27, 2024 and adjusted for a one-for-ten reverse stock split effective June 27, 2024, while the 7,394-share grant was made on January 29, 2025.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026. The award covers 31,700 shares of common stock under an employee stock option, with an exercise price of $22.49 per share and an expiration date of January 29, 2035. The filing shows this as a compensation-related acquisition, not an open-market buy or sale, and lists 31,700 derivative shares held following the transaction.